Leukemia, T-Cell clinical trials

The registry lists 33 studies for Leukemia, T-Cell across 6 countries. 9 are recruiting or about to start. 8 of them are mainly about Leukemia, T-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28. Counting its 3 narrower conditions too, such as Leukemia, Large Granular Lymphocytic: 225 studies, 38 open.

Get an email when these change. Save the Leukemia, T-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 10
Recruiting: 8
Status unknown: 7
Terminated: 4
Withdrawn: 2
Not yet recruiting: 1

Phase

Phase 1: 18
Phase 2: 15
Phase 3: 4
Early Phase 1: 1

Where

United States: 14
China: 14
France: 1
Spain: 1
Italy: 1
Georgia: 1

Who runs them

Beijing Boren Hospital (3) · National Cancer Institute (NCI) (3) · Nanfang Hospital, Southern Medical University (2) · Hebei Senlang Biotechnology Inc., Ltd. (2) · iCell Gene Therapeutics (2) · Gyala Therapeutics (1) · Portola Pharmaceuticals (1) · Huda Salman (1)

What is being tested here

Drugs under test in Leukemia, T-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Mogamulizumab	1	0	1
Tucidinostat	0	2	2
Everolimus	0	0	1
Palbociclib	0	0	1
Resimmune	0	0	1
Daclizumab	0	0	1
Forodesine hydrochloride	0	0	1
Forodesine	0	0	1
Cyclosporine	0	0	1
Ruxolitinib	0	0	1

Drug classes tested here HDAC inhibitors 3

Coming up

1phase 3 study under way

1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Nov 2027The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies · AVM Biotechnology Inc

Who these studies take

Of the 8 Leukemia, T-Cell studies recruiting now, 3 (38%) set no upper age limit and 3 (38%) stop at 75 or younger. 6 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	4 (50%)	4 (50%)
18	8 (100%)	8 (100%)
30	6 (75%)	6 (75%)
40	6 (75%)	6 (75%)
50	6 (75%)	6 (75%)
65	6 (75%)	6 (75%)
75	6 (75%)	6 (75%)
85	5 (63%)	5 (63%)

Across all 33 studies, recruiting or not: 48% stop at 75 or younger and 21% at 65; 67% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 33 of 33. search them.